Feature | Radial Access | October 18, 2015

Radial Access Has Similar Ischemic Outcomes, Lower Bleeding to Femoral at One Year

Results of the DRAGON trial presented at TCT 2015

transradial access, TRI, DRAGON trial, TCT 2015, non-inferiority, transfemoral access, TFO

October 18, 2015 — Results from a prospective randomized trial of transradial (TRI) versus transfemoral (TFO) access in patients undergoing percutaneous coronary intervention found that TRI was non-inferior in terms of clinical effectiveness at one year and superior in reducing major bleeding complications at seven days compared to TFI.

Findings from the DRAGON study were presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

Traditionally, PCI has been performed by accessing the heart with a catheter that is inserted into the femoral artery in the groin. A more recent technique which accesses the heart from the transradial artery in the arm has been gaining popularity. To examine the effectiveness of the TRI approach, the DRAGON study enrolled 2,042 patients who were assigned by a 2:1 randomization to the TRF group (n=1,366) or TFI group (n=676).  The 12-month follow-up rate was 97.6 percent [TRI (N=1,212); TFI (N=527)].

The primary endpoint of the study was the major adverse cardiac or cerebrovascular event (MACCE)-free rate at 12 months post-procedure. After adjustment, the MAACE-free rate after one year for TRI was 95.8 percent compared to 95.5 percent for TFI. The difference [95 percent Cl] between TFI and TRI was -0.3 percent ( [-1.7 percent; 1 percent] Pnoninferiority=<0.001.) Therefore, non-inferiority was met as the upper 95 percent confidence bound was less than the non-inferiority margin of 5 percent.

For the secondary endpoint of freedom from major bleeding complications (BARC definition type three or five) at seven days post-procedure, rates were 99.9 percent vs. 99 percent (after adjustment). The difference [95 percent Cl] between TFI and TRI was -0.9 percent ([-1.4 percent; -0.4 percent], Psuperiority<0.001).

“The results of the DRAGON study show that in real-world clinical practice the transradial approach is as effective as the transfemoral approach for angioplasty after one year,” said lead investigator Shigeru Saito, M.D. Saito is the director of cardiology and catheterization laboratories and vice-director at Shonan Kamakura General Hospital in Kanagawa, Japan.

“In addition, the transradial approach is associated with less major bleeding at one week post-procedure. For some patients undergoing PCI, the transradial approach may be more desirable.”

The DRAGON trial was supported in part by a research grant from Terumo Medical Products (Shanghai). Saito reported financial interest with Terumo and Boston Scientific.

For more information: www.tctconference.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Overlay Init